Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Disease area: Respiratory infections

Abstract

Objectives: to determine the role of immune stimulatory therapy in patients with severe CAP.Methods: 23 patients (age – 56,1±3,36 years, men – 13 (56,5%)) with verified severe CAP without HIV, divided into two groups: group 1 – 11 (47,8%) patients with severe CAP with using of immunomodulator glutamyl-glycine cysteinyl disodium from tiopoetyns; group 2 – 12 (52,2%) patients with severe CAP without immunomodulator. Control group included 10 clinically healthy individuals (age – 51,1±5,6 years, men – 6 (60%)). General analysis, biochemical analysis, serum procalcitonin (PCT), blood CD4, CD8 prior antibacterial treatment (ABT) (visit 1), on 3 – 5 day of ABT (visit 2), on 7–10 day of ABT (visit 3), statistic.Results: On visit 1 groups were comparable on initial severity, inflammatory level, immunological status. On visit 2 normalization of body temperature, consciousness, bilirubin, creatinine, PCT were more often in patients in group 1.On visit 3 in patients of group 1 the level of CD4 has increased by almost 72%, while in the subgroup 2 – only by 50%.

Dynamics of the immunological parameters in patient with severe CAP

Parameter	Control group	Group 1	Group 1	Group 2	Group 2
		Visit 1	Visit 3	Visit 1	Visit 3
CD4, mcl-1	1037±84,7	227,3±45,7*†	808,0±85,9Ù	333,8±73,9*†	500,7±86,9*
CD8, mcl-1	644,7±75,7	187,7±54,3*†	492,2±90,4	222,3±37,0*	348,5±83,9

Conclusions: 1) some patients with severe CAP has decrease of immune markers CD4, CD8 less than 500 mcl-1; 2) adding of immunomodulator during5–7 days prior adjuvant therapy of severe CAP increases the number of CD4 by almost 75% compared to the initial.
Notes: * - p1,2-c<0,05 on Mann-Whitney; Ù - p1-2<0,05 on Mann-Whitney; † - p1-2<0,05 on Wilcoxon

Rating:

Share or cite this content

Citations should be made in the following way:
K. Bielosludtseva, T. Kireeva (Dnipropetrovsk, Ukraine). Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP). Eur Respir J 2014; 44: Suppl. 58, 2552

Member's Comments

No comment yet.

Related content which might interest you: Clinical and laboratory predictors of survival in patients with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections Year: 2014 Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Immunoglobulin levels and severity of community-acquired pneumonia (CAP) Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections Year: 2014 Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Survival predictors of severe community-acquired pneumonia (CAP): Multivariate analysis of immunological and inflammatory parameters Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Community-acquired pneumonia with severe sepsis: Etiology and prognosis Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Analysis of the lethal outcomes in patients with severe pneumonia Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 PICTURE: Clinical pattern and pneumococcal infections in patients with community-acquired pneumonia (CAP) admitted to emergency department Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Ventilator-associated pneumonia (VAP) pathogenic microorganisms eradication and persistence during antimicrobial therapy Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Effect of acenitobacter baumanii positive pneumonia on morbidity and mortality of patients Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015 The neutrophil/lymphocyte ratio in predicting outcome for hospitalized patients with community-acquired pneumonia Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections Year: 2014 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Assessment of severity of intensive care unit-acquired pneumonia and association with aetiology Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 The outcome of community-acquired pneumonia in patients with COPD, asthma and ILD - a case-control study Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Features of pneumonia diagnostics in burn trauma patients Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Cardiac autonomic alterations impact early and late outcomes in patients with community-acquired pneumonia Source: Annual Congress 2013 –Manifestations, scores and prognosis of community-acquired pneumonia Year: 2013 Impact of candida spp. colonization of respiratory tract in patients with intensive care unit-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013